NICE final draft guidance recommends risankizumab, alone or with methotrexate, for active psoriatic arthritis in adults whose disease has not responded well enough to DMARDs or who cannot tolerate them.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us